12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Prochymal: Development discontinued

Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) disclosed in its 4Q11 earnings that it discontinued development of Prochymal, which was in Phase III testing for GvHD. As a result of Sanofi's decision, Osiris said it will regain exclusive rights to Prochymal outside...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >